ProShare Advisors
ORKA

ProShare Advisors’s Oruka Therapeutics ORKA Stock Holding History

ProShare Advisors’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$816K Buy
8,570
+814
+10% +$54.2K ﹤0.01% 858
2026
Q1 		$380K Sell
7,756
-1,433
-16% -$49.8K ﹤0.01% 1205
2025
Q4 		$279K Buy
+9,189
New +$256K ﹤0.01% 1503

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

ProShare Advisors's ORKA Position: Q2 2026 in Review

ProShare Advisors increased its Oruka Therapeutics (ORKA) stake by 10% in Q2 2026, buying an estimated $54.2K and bringing the position to 8,570 shares worth $816K. The position accounts for ﹤0.01% of the portfolio, ranked #858.

ProShare Advisors first reported a position in ORKA in Q4 2025 and has held it in 3 quarters since. 256 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • ProShare Advisors held 8,570 shares of Oruka Therapeutics worth $816K as of Q2 2026.
  • ProShare Advisors bought 814 Oruka Therapeutics shares in Q2 2026, an estimated $54.2K.
  • Oruka Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #858 holding.
  • ProShare Advisors first reported a position in Oruka Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 256 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.